The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of ubenimex combined with pembrolizumab, nab-paclitaxel, and carboplatin for previously untreated advanced squamous non–small cell lung cancer: TORG2241(UBE-Q).
 
Akane Narumi
Honoraria - AstraZeneca; Chugai Pharma; Kirin Pharmaceuticals; Takeda
 
Shinji Nakamichi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical
 
Kaoru Kubota
Honoraria - Chugai Pharma; Pfizer
Research Funding - Chugai Pharma (Inst)
 
Kotone Matsuyama
Consulting or Advisory Role - Boehringer Ingelheim; Nippon Kayaku
 
Toshihiro Misumi
Honoraria - Miyarisan pharmaceutical
Consulting or Advisory Role - Anaut Inc.
 
Kaoru Chiba
No Relationships to Disclose
 
Yuka Kato
Consulting or Advisory Role - Daiichi Sankyo Co., Ltd.
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo Company; Janssen; Lilly Japan; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst)
 
Hiroshi Nokihara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca; Chugai Pharma; Henlius; MSD
 
Ryosuke Ochiai
No Relationships to Disclose
 
Yukiko Nakamura
Research Funding - AstoraZeneca (Inst); MSD (Inst); Sanofi (Inst); Shanghai Junshi BioSciences (Inst)
 
Nobuaki Kobayashi
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo Nordics; Kyowa Kirin International; Lilly Japan; MSD; Ono Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma
 
Hiroshi Wakui
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyouwa Kirin; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Naoki Furuya
No Relationships to Disclose
 
Ayae Saiki
No Relationships to Disclose
 
Masayuki Shirasawa
Honoraria - Asahi Kasei Pharma Cormoration; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical
 
Susumu Takeuchi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Churchill Pharmaceuticals; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Haruhiro Saito
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Ono Pharmaceutical (Inst)
 
Shinobu Hosokawa
Speakers' Bureau - AstraZeneca Japan
 
Katsuhiko Naoki
Honoraria - asahi kasei; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Insmed; Janssen; Kyorin; Lilly; Merck; MSD; Novartis; Olympus; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Ltd
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst)